Abstract
BACKGROUND: Medication interactions account for a significant proportion of overanticoagulation in warfarin users. However, little is known about the incidence or degree of interaction with commonly used oral antibiotics.
OBJECTIVE: To investigate the incidence and degree of overanticoagulation associated with commonly used oral antibiotics.
DESIGN: Retrospective cohort study of patients using warfarin who initiated an antibiotic (azithromycin, levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin for clinical indications between January 1998 and December 2002. The incidence of international normalized ratio (INR) elevation and the degree of change and bleeding events after institution of either medication type was recorded.
SUBJECTS: Patients at a university-affiliated Veteran’s Affairs Medical Center.
RESULTS: The mean change in INR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean INR changes in the antibiotic groups were all statistically different from the terazosin group. The incidence of supratherapeutic INR was 5% for terazosin, 31% for azithromycin, 33% for levofloxacin, and 69% for TMP/SMX. The incidence of absolute INR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for levofloxacin, and 44% for TMP/SMX.
CONCLUSIONS: Among acutely ill outpatients, oral antibiotics (azithromycin, levofloxacin, and TMP/SMX) increase the incidence and degree of overanticoagulation.
References
Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2003;139:893–900.
Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant therapy. Chest. 2001;119:108S-21.
Cannegueter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11–7.
Glasheen JJ, Fugit RV. How warfarin interacts with common antibiotics. Emerg Med. 2004;36:30C-30I.
Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121:676–83.
Penning-van Beest FJ, Van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther. 2001;69:451–7.
Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Hematol. 1998;103:422–4.
Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physician. 1999;59:635–46.
Beckey NP, Parra D, Colon A. Retrospective evaluation of a potential interaction between azithromycin and warfarin in patients stabilized on warfarin. Pharmacotherapy. 2000;20:1055–9.
Tatro DS, ed. Drug Interaction Facts. St. Louis, Mo: Facts and Comparisons; 2003.
McCall KL, Anderson HG, Jones AD. Determination of the lack of a drug interaction between azithromycin and warfarin. Pharmacotherapy. 2004;24:188–94.
Rindone JP, Kuey CL, Jones WN, Garewal HS. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin. Clin Pharm. 1991;10:136–8.
Bianco TM, Bussey HI, Farnett LE, Linn WD, Roush MK, Wong YW. Potential warfarin-ciprofloxacin interaction in patients receiving long-term anticoagulation. Pharmacotherapy. 1992;12:435–9.
Israel DS, Stotka J, Rock W, t al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. CID. 1996;22:251–6.
Liao S, Palmer M, Fowler C, Nayak RK. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. J Clin Pharmacol. 1996;36:1072–7.
Yamreudeewong W, Lower DL, Kipatrick DM, Enlow AM, Burrows MM, Greenwood MC. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy. Pharmacotherapy. 2003;23:333–8.
Glasheen JJ, Fugit RV, Prochazka AV. Effect of levofloxacin coadministration on the international normalized ratios during warfarin therapy—a comment. Pharmacotherapy. 2003;23:1079–80.
O’Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxasole interaction in humans. Ann Intern Med. 1979;91:34–6.
Author information
Authors and Affiliations
Corresponding author
Additional information
Drs. Glasheen, Fugit, and Prochazka have no financial disclosures, and have no conflicts of interest to report for this article or this research.
Dr. Glasheen was affiliated with the Department of Medicine. Division of General Internal Medicine, at the Denver VA Medical Center, University of Colorado Health Science Center, Denver, CO, during the data collection phase of this research.
Dr. Glasheen certifies that the has had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All above-stated authors have contributed to the design, execution, analysis, and writing of this manuscript.
Rights and permissions
About this article
Cite this article
Glasheen, J.J., Fugit, R.V. & Prochazka, A.V. Brief report: The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens. J GEN INTERN MED 20, 653–656 (2005). https://doi.org/10.1007/s11606-005-0113-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11606-005-0113-5